Informatika tanítása űrszonda modellel

Az alkalmazott informatika egyik példaértékű gyakorlati megvalósítási területe a kísérleti űrszonda modellek építése a magyar felsőoktatásban. 1997 óta több HUNVEYOR űrszonda modell épült Magyarországon a felsőoktatási intézményekben. Az oktatás segítésén túl e munkáknak az volt a célja, hogy megismerkedjenek a tanárok és a hallgatók a planetáris kutatások fontosabb informatikai és űrtechnológiáival

Informatika tanítása űrszonda modellel

Az alkalmazott informatika egyik példaértékű gyakorlati megvalósítási területe a kísérleti űrszonda modellek építése a magyar felsőoktatásban. 1997 óta több HUNVEYOR űrszonda modell épült Magyarországon a felsőoktatási intézményekben. Az oktatás segítésén túl e munkáknak az volt a célja, hogy megismerkedjenek a tanárok és a hallgatók a planetáris kutatások fontosabb informatikai és űrtechnológiáival

Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis

Metformin is the first-choice drug for patients with Type 2 diabetes, and this therapy is characterized by being weight neutral. However, in the elderly an additional unintentional weight loss could be considered as an adverse effect of the treatment.We aimed to perform a meta-analysis of placebo-controlled studies investigating the body weight changes upon metformin treatment in participants older than 60 years.PubMed, EMBASE and the Cochrane Library were searched. We included at least 12 week-long studies with placebo control where the mean age of the metformin-treated patients was 60 years or older and the body weight changes of the patients were reported. We registered our protocol on PROSPERO (CRD42017055287).From the 971 articles identified by the search, 6 randomized placebo-controlled studies (RCTs) were included in the meta-analysis (n = 1541 participants). A raw difference of -2.23 kg (95% CI: -2.84 --1.62 kg) body weight change was detected in the metformin-treated groups as compared with that of the placebo groups (p<0.001). Both total cholesterol (-0.184 mmol/L, p<0.001) and LDL cholesterol levels (-0.182 mmol/L, p<0.001) decreased upon metformin-treatment.Our meta-analysis of RCTs showed a small reduction of body weight together with slight improvement of the blood lipid profile in patients over 60 years. With regard to the risk of unintentional weight loss, metformin seems to be a safe agent in the population of over 60 years. Our results also suggest that metformin treatment may reduce the risk of major coronary events (-4-5%) and all-cause mortality (-2%) in elderly diabetic populations

Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease : A meta-analysis

Despite the high rate of postoperative recurrence (POR) in Crohn's disease (CD), there is no widely accepted consensus on its prevention.To compare the efficacy of biological and conventional therapies in preventing POR of CD.We searched four electronic databases up to April 2019 for articles that examined the efficacy of different preventive therapies against POR. Our PICO was: (P) adults with CD who underwent intestinal resection, (I) biological agents, (C) conventional therapies or a placebo, and (O) clinical, endoscopic, and histological POR.Anti-TNFα agents were significantly better in preventing clinical, endoscopic, severe endoscopic and histological POR compared to conventional therapies (OR: 0.508, 95% CI: 0.309-0.834, P = 0.007; OR: 0.312, 95% CI: 0.199-0.380, P < 0.001; OR: 0.195, 95% CI: 0.107-0.356, P < 0.001; and OR: 0.255, 95% CI: 0.106-0.611, P = 0.002, respectively), as well as in the subgroup of nonselected CD patients (OR: 0.324, 95% CI: 0.158-0.664, P = 0.002; OR: 0.225, 95% CI: 0.124-0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070-0.877, P = 0.031, respectively). Infliximab and adalimumab proved to be equally effective in preventing endoscopic POR.Anti-TNFα agents are more effective in preventing clinical, endoscopic and histological POR than conventional therapies, even in nonselected CD patients

Anti-TNF[alfa] agents are the best choice in preventing postoperative Crohn's disease: a meta-analysis

L